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Sir,
Thank you for the opportunity to comment on this interesting
letter, which addresses some important methodological issues in
studies of risk factors with post hoc genotyping. In their collection
of French families in which one or more child is affected by AT,
d’Almeida and co-workers have shown how potential biases,
introduced by late genotyping of relatives with certain outcomes,
can be addressed by various analytical approaches. They then
compare and discuss the results.
In the Nordic study, genotyping of probands and parents
was generally completed during the diagnostic work-up of the
AT patients, that is, at the date of start of follow-up for subsequent
breast and other cancers. Supplementary genotyping of
other family members was usually conducted years or decades
later, either among survivors who were willing to participate or
among relatives who had died from breast cancer and for whom
tissue blocks were available. As the study hypothesis was
that carriers of an ATM allele are at increased risk for breast
cancer and perhaps other potentially deadly diseases, we
considered that we could not backdate the result of the gene
testing, that is, reallocate the person-years at risk from the start of
follow-up of these relatives, without running the risk of introdu-
cing differential misclassification. As the date of testing was not
available for all relatives, we decided not to change the gene
probability scores of the tested persons but only to change the
scores of their ancestors. We thus chose to retain some random
gene exposure misclassification due to the initial allocation of
carrier probability, defined by location in a family, rather than risk
introducing non-random misclassification, which can lead to
overestimation of risks.
It is reassuring that d’Almeira and co-workers report in their
letter that some, limited variation in breast cancer risk estimates
was found with each of the three approaches in the French
material, and that the mothers in this study – as in the Nordic
study – clearly showed a very high risk for breast cancer. In the
Nordic study, we concluded that our data did not convincingly
point to a trend of increasing risk with each increment in the
probability of being a gene carrier, indicating that we should
consider other mechanisms than a genetic one as the cause of
breast cancer in these families. We nevertheless reported a
significantly increased risk for breast cancer among female
relatives below the age of 55 years who had an estimated gene
carrier probability of 0.25, and we acknowledged that the estimated
trend in breast cancer risk by increasing gene carrier probability
was based on a very limited number of outcomes. As pointed out
by d’Almeira and co-workers, international collaboration is the
only means of addressing this problem in an epidemiological
design.
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